2017 Subject Index
1H-NMR................................................................................. 49
2,3-dihydro-1,4-benzodioxin-6-amine.................................... 49
Acetohydrazide...................................................................... 285
Acinetobacter.......................................................................... 13
Activity of melatonin................................................................ 75
Adenosine A2B receptors........................................................ 19
Agmatine............................................................................... 127
AMPK................................................................................... 207
Androgen receptor................................................................ 274
Anti-inflammatory................................................................. 231
Anti-inflammatory activity..................................................... 108
Antibacterial activity.............................................................. 157
Antibacterial potential............................................................. 49
Antineoplastic........................................................................ 304
Antioxidant............................................................................ 311
Antioxidant activity................................................................ 174
Antiproliferative...................................................................... 29
Antitubercular activity........................................................... 157
Antiviral activity.................................................................... 157
AP-PCR................................................................................... 13
Apoptosis....................................................................... 169,222
Artemisia absinthium............................................................ 222
Artificial neural networks...................................................... 213
Arylidenehydrazide............................................................... 157
Asteraceae............................................................................. 290
AUC...................................................................................... 108
Benzimidazole....................................................................... 285
Biodegradable......................................................................... 34
Biomechanic............................................................................ 65
cAMP...................................................................................... 19
Cancer cells.......................................................................... 222
Carbonic anhydrase................................................................. 9
Carvacrol................................................................................ 29
Cell death.............................................................................. 169
Characterization.............................................................. 34,280
Checkerboard......................................................................... 13
Chemotherapy....................................................................... 304
CHO cells............................................................................. 185
Chrysophthalmum montanum.............................................. 290
Clinical trials.......................................................................... 84
Clonazepam.......................................................................... 251
Clove oil................................................................................ 201
Co-crystal............................................................................. 280
Cobalt ferrite nanoparticle.................................................... 169
Colistin.................................................................................... 13
Comet assay.......................................................................... 185
Cost saving........................................................................... 304
Croscarmellose sodium.......................................................... 40
CYP....................................................................................... 319
Cytotoxic activity................................................................... 290
Cytotoxicity.............................................................. 201,222,231
Desloratadine....................................................................... 148
Dexketoprofen trometamol........................................................ 1
Diclofenac sodium............................................................... 1,56
Dirithromycin....................................................................... 191
Disintegration......................................................................... 40
Dissolution................................................................ 40,120,280
DNA damage.......................................................... 169,185,257
Donepezil.............................................................................. 164
DPPH................................................................................... 179
Drug delivery..................................................................... 34,56
Drug pricing......................................................................... 264
Drug waste........................................................................... 304
EDCF.................................................................................... 207
Endemic................................................................................ 134
Endometrial cancer............................................................... 141
Endothelium.......................................................................... 207
Enzyme activation................................................................. 164
Epidermal growth factor receptor kinase............................. 285
EROD activity....................................................................... 174
Ethics.................................................................................... 264
Eudragit® RS100................................................................... 148
Eugenol................................................................................. 201
Extended-release tablets........................................................ 213
First-derivative synchronous spectrofluorimetry.................. 251
Free radical scavenging activity............................................ 179
Genotoxicity.......................................................................... 201
GSTM1................................................................................. 237
GSTT1.................................................................................. 237
Gynecologic cancers............................................................. 324
Health effects......................................................................... 311
Health policies...................................................................... 264
HeLa....................................................................................... 29
Herbicide.............................................................................. 185
High performance liquid chromatography........................... 179
Histopathology................................................................. 65,243
HPLC.................................................................................... 148
Human CAI........................................................................... 164
Human CAII......................................................................... 164
Imidazo[2,1-b]thiazole......................................................... 157
In vivo bioavailability study................................................... 120
IND......................................................................................... 84
Indion 414............................................................................... 40
Indomethacin........................................................................ 108
Inflammation............................................................. 19,274,324
Inhibition................................................................................... 9
Inhibitory.............................................................................. 285
Inos....................................................................................... 231
Insecticidal activity................................................................ 290
Interleukin 6............................................................................ 19
Internal and external predictability....................................... 120
Ischemia reperfusion injury.................................................. 257
IVIVC.................................................................................... 120
Kollidon® SR......................................................................... 191
Lead.......................................................................................... 9
Leaf and stem anatomy......................................................... 134
Leguminosae......................................................................... 134
Lipid peroxidation................................................................. 174
Lipoxygenase.......................................................................... 49
Lung cancer.......................................................................... 319
Lycopene............................................................................... 311
Mass spectrometer................................................................ 294
MDA..................................................................................... 179
Medicinal plants.................................................................... 222
Melatonin................................................................................ 75
Memantine............................................................................ 164
Microspheres........................................................................ 243
Molecular docking.................................................................. 34
MTT................................................................................. 95,231
Nanoparticle......................................................................... 148
Naproxen sodium.................................................................. 120
Naringenin................................................................................ 9
Neuro-fuzzy logic.................................................................. 213
Neutral red.............................................................................. 95
NF-kb.................................................................................... 231
NKX3.1................................................................................. 274
Non-small cell lung carcinoma............................................. 237
NSAID................................................................................... 274
Ocular drug delivery............................................................. 191
Ononis.................................................................................. 134
Origanum acutidens............................................................... 29
Ovarian cancer..................................................................... 141
Oxazolidinones..................................................................... 174
Paroxetine hydrochloride...................................................... 251
Pathway................................................................................ 324
Patient rights......................................................................... 264
Pendimethalin....................................................................... 185
Pharmaceutical industry....................................................... 264
Pharmacists.......................................................................... 264
Pharmacoeconomy............................................................... 304
Pharmacological activity....................................................... 201
Phase 0................................................................................... 84
Phytoconstituents.................................................................. 324
Phytomelatonin....................................................................... 75
Phytotoxic activity.................................................................. 290
Pistacia atlantica..................................................................... 65
Plant phenolics........................................................................ 95
PLGA...................................................................................... 56
Poloxamers............................................................................. 56
Poly(e-caprolactone)............................................................... 56
Polymeric nanoparticles....................................................... 191
Polymorphism................................................................ 237,319
Preclinical testing.................................................................... 84
Prostate cancer..................................................................... 274
Protein expression................................................................ 237
Pseudo ternary phase diagram............................................. 108
Pycnogenol............................................................................ 257
Quality by design.................................................................. 213
Quercetin.............................................................................. 280
Quetiapine fumarate............................................................. 213
Radical scavenging................................................................. 29
Rat......................................................................................... 127
Response to chemotherapy.................................................... 319
Rho-kinaz.............................................................................. 207
Salicylic acid............................................................................. 1
Scorzonera latifolia............................................................... 179
sE-cadherin........................................................................... 141
Secondary metabolites.......................................................... 324
Self emulsifying drug delivery system.................................... 108
Skeletal muscle........................................................................ 19
Skin......................................................................................... 65
Skin reaction......................................................................... 127
Sodium starch glycolate.......................................................... 40
Solvent evaporation............................................................... 280
Statistical assessment............................................................ 294
Subcutaneous route............................................................... 127
Substance abuse.................................................................... 294
Succinic acid......................................................................... 280
Survival................................................................................. 319
Sustained release.................................................................. 120
Synthesis............................................................................... 174
Tanacetum argenteum subsp. argenteum............................. 231
TGF-b1................................................................................. 141
Thermosensitive hydrogel....................................................... 56
Tigecycline.............................................................................. 13
Time-kill.................................................................................. 13
Toxicity........................................................................... 127,201
Turkey................................................................................... 134
UPLC........................................................................................ 1
Urine..................................................................................... 294
Vaccine delivery.................................................................... 243
Validation.................................................................................. 1
Vitronectin............................................................................. 141
Wet granulation.................................................................... 213
Wetting.................................................................................... 40
Wound healing........................................................................ 65
Zeta potential ....................................................................... 108